


1/37

FIG. 1


TGF- β 1 in Cell Cultures Treated with Compound C
During 20 minute Ischemia



2/37

FIG. 2


TGF- β 2 in Cell Cultures Treated with Compound C
During 20 minute Ischemia



3/37

FIG. 3


TGF- β Neutralizing Antibody Blocks the
Neuroprotective Effect of Compound C



4/37

FIG. 4


FGF Neutralizing Antibody Does Not Block
Neuroprotective Effects of Compound C in vitro



5/37

FIG. 5


TGF- β Neutralizing Antibody Blocks Neuroprotective
Effect of Compound C Against 2 hour MCAO



6/37

FIG. 6

**TGF- β 1 in Dialysate from Rats Treated with Compound C
During Ischemia and Reperfusion**



7/37

FIG. 7A






FIG. 7B



8/37

FIG. 8



9/37

FIG. 9A





FIG. 9B



10/37

FIG. 10A






FIG. 10B



11/37


FIG. 11



12/37

FIG. 12


MNCV



13/37

FIG. 13


Presence of Limb Shaking at 210 Days



14/37

FIG. 14


Gait in SOD Transgenic Mice at 210 Days



15/37

FIG. 15


Dragging Hind Limbs in SOD
Transgenic Mice at 210 Days



16/37

FIG. 16


Crossing of Limbs in SOD
Transgenic Mice at 210 Days



17/37

FIG. 17


Righting Reflex in SOD
Transgenic Mice at 210 Days



18/37

FIG. 18

Mortality in SOD Mice




19/37

FIG. 19

Kaplan-Meier Survival Curve of Mice After
Treatment with Compound B and Vehicle

NAALADASE: ALS STUDY
OVERALL SURVIVAL



20/37

FIG. 20

NAALADase Inhibitors Reverse Hyperalgesia and
Hypoalgesia in Well-Established Disease (in-house)





FIG. 21

NAALADase Inhibition Reverses Motor Nerve
Conduction Deficit in Well-Established Diabetes



22/37

FIG. 22

NAALADase Inhibition Reverses Sensory Nerve
Conduction Deficit in Well-Established Diabetes





FIG. 23


NAALADase Inhibition Attenuates Both Hyper-
and Hypoalgesia in STZ-Diabetic Rats



24/37

FIG. 24

MNCV on STZ-Rats Treated with Compound D/Vehicle



25/37

FIG. 25

SNCV on STZ-Rats Treated with Compound D/Vehicle





FIG. 26

Compound D Reverses Sensory Nerve Conduction Velocity Deficit in Established Diabetes



27/37

FIG. 27

Compound D Reverses Motor Nerve Conduction Velocity Deficit in Established Diabetes






FIG. 28



29/37

FIG. 29


NCV in db/db Genetic Mouse Model of Diabetes
4 months of diabetes (pre-drug treatment)



30/37

FIG. 30

NCVs in db/db mice
treated with Compound F (1mg/kg)/ Vehicle



31/37

FIG. 31



BEST AVAILABLE COPY

32/37


FIG. 32



BEST AVAILABLE COPY

33/37

FIG. 33




BEST AVAILABLE COPY


34/37

FIG.34

Rotarod Tests on Transgenic HD Mice After the
Treatments With Compound B (30 mg/kg/day, orally)




35/37

FIG. 35

36/37

FIG. 36



37/37

FIG. 37A




FIG. 37B

